NEUMORA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.45 USD | -2.48% |
|
-1.36% | -44.57% |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 2,604 | 1,508 | - | - |
| Enterprise Value (EV) 1 | 2,140 | 1,030 | 814.4 | 1,508 |
| P/E ratio | -4.7 x | -6.38 x | -6.03 x | -5.54 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | - | - | 41.6 x |
| EV / Revenue | - | - | - | 41.6 x |
| EV / EBITDA | -8.51 x | -4.21 x | -3 x | -4.63 x |
| EV / FCF | -13.1 x | -4.87 x | -3.27 x | -5.14 x |
| FCF Yield | -7.64% | -20.5% | -30.6% | -19.5% |
| Price to Book | 5.77 x | 5.42 x | 3.5 x | 2.69 x |
| Nbr of stocks (in thousands) | 152,703 | 159,524 | - | - |
| Reference price 2 | 17.05 | 9.450 | 9.450 | 9.450 |
| Announcement Date | 3/7/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | 36.21 |
| EBITDA 1 | - | -251.4 | -244.3 | -271.2 | -325.8 |
| EBIT 1 | - | -252.1 | -253.5 | -286.9 | -338.6 |
| Operating Margin | - | - | - | - | -935.19% |
| Earnings before Tax (EBT) 1 | - | -235.7 | -244.4 | -284.3 | -418.9 |
| Net income 1 | -130.9 | -235.9 | -237.3 | -270.8 | -323 |
| Net margin | - | - | - | - | -892.1% |
| EPS 2 | -0.6100 | -3.630 | -1.482 | -1.566 | -1.706 |
| Free Cash Flow 1 | - | -163.4 | -211.5 | -249 | -293.5 |
| FCF margin | - | - | - | - | -810.54% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - |
| Announcement Date | 5/2/23 | 3/7/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - |
| EBITDA 1 | -56.69 | -113.8 | - | -60 | -62 | -62 | - | - |
| EBIT 1 | -56.86 | -114 | -60.07 | -62.3 | -65.39 | -67.94 | - | - |
| Operating Margin | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -53.03 | -108.5 | -53.72 | -60.73 | -63.97 | -65.93 | - | - |
| Net income 1 | -53.03 | -108.7 | -53.72 | -60.73 | -63.97 | -65.93 | - | - |
| Net margin | - | - | - | - | - | - | - | - |
| EPS 2 | - | -0.7100 | -0.3400 | -0.3745 | -0.3942 | -0.3922 | -0.3800 | -0.3900 |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 11/1/23 | 3/7/24 | 5/7/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | - | 464 | 478 | 693 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | -163 | -212 | -249 | -294 |
| ROE (net income / shareholders' equity) | - | -51.2% | -58.6% | -65.5% | -51.6% |
| ROA (Net income/ Total Assets) | - | -51.2% | -53.6% | -58.6% | -47.4% |
| Assets 1 | - | 461.2 | 442.5 | 462.4 | 680.9 |
| Book Value Per Share 2 | - | 2.950 | 1.740 | 2.700 | 3.520 |
| Cash Flow per Share 2 | - | -2.510 | -0.8900 | -0.9500 | - |
| Capex 1 | - | 0.12 | 0.1 | 0.1 | - |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 5/2/23 | 3/7/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
9.45
USD
Average target price
23.84
USD
Spread / Average Target
+152.29%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -44.57% | 1.51B | |
| +44.48% | 55.07B | |
| +44.30% | 40.22B | |
| -0.86% | 41.79B | |
| -7.59% | 28.17B | |
| +12.30% | 26.28B | |
| -21.83% | 18.93B | |
| +7.15% | 13.03B | |
| +29.40% | 12.26B | |
| +25.15% | 12.21B |
- Stock Market
- Equities
- NMRA Stock
- Financials Neumora Therapeutics, Inc.